FDA Sets Limits On Public Comment Process In Levothyroxine Generic Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott does not have the right to demand an advisory committee meeting or a public workshop on levothyroxine issues before generic approvals, FDA told the company